
Massimo Campieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1812347/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology, 2000, 119, 305-309.	0.6	1,373
2	Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology, 2003, 124, 1202-1209.	0.6	1,048
3	Effect of an Enteric-Coated Fish-Oil Preparation on Relapses in Crohn's Disease. New England Journal of Medicine, 1996, 334, 1557-1560.	13.9	729
4	VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis. American Journal of Gastroenterology, 2005, 100, 1539-1546.	0.2	659
5	Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis. American Journal of Pathology, 1999, 155, 331-336.	1.9	259
6	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. Journal of Crohn's and Colitis, 2016, 10, 296-305.	0.6	252
7	Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunology and Medical Microbiology, 2003, 38, 165-172.	2.7	241
8	Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney International, 2001, 60, 1097-1105.	2.6	204
9	Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. American Journal of Gastroenterology, 2001, 96, 2691-2699.	0.2	193
10	Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?. Gastroenterology, 1999, 116, 1246-1249.	0.6	188
11	High-Dose Probiotics for the Treatment of Active Pouchitis. Diseases of the Colon and Rectum, 2007, 50, 2075-2084.	0.7	179
12	Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study VS mesalamine. Gastroenterology, 2000, 118, A781.	0.6	171
13	Bacteria as the cause of ulcerative colitis. Gut, 2001, 48, 132-135.	6.1	169
14	A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology, 1986, 91, 1490-1494.	0.6	150
15	Mucosa-associated microbiota dysbiosis in colitis associated cancer. Gut Microbes, 2018, 9, 131-142.	4.3	142
16	A New Oral Delivery System for 5-ASA: Preliminary Clinical Findings for MMX. Inflammatory Bowel Diseases, 2005, 11, 421-427.	0.9	133
17	Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials. American Journal of Gastroenterology, 2005, 100, 1780-1787.	0.2	124
18	Antibiotics and probiotics in treatment of inflammatory bowel disease. World Journal of Gastroenterology, 2006, 12, 3306.	1.4	122

#	Article	IF	CITATIONS
19	Variable Response to Probiotics in Two Models of Experimental Colitis in Rats. Inflammatory Bowel Diseases, 2002, 8, 399-406.	0.9	115
20	Probiotics in infective diarrhoea and inflammatory bowel diseases. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 489-493.	1.4	114
21	Loss of <i><scp>miR</scp>â€101</i> expression promotes Wnt/ <i>β</i> â€catenin signalling pathway activation and malignancy in colon cancer cells. Journal of Pathology, 2013, 229, 379-389.	2.1	105
22	<i>Lactobacilli, bifidobacteria</i> and <i>E. coli</i> nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World Journal of Gastroenterology, 2006, 12, 5978.	1.4	104
23	Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Digestive Diseases and Sciences, 1992, 37, 1890-1897.	1.1	88
24	Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-α in ulcerative colitis. American Journal of Gastroenterology, 1999, 94, 2923-2928.	0.2	74
25	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Digestive Diseases and Sciences, 1992, 37, 29-32.	1.1	70
26	Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. Digestive Diseases and Sciences, 1993, 38, 1843-1850.	1.1	68
27	Antimicrobials in the Management of Inflammatory Bowel Disease. Digestion, 2006, 73, 77-85.	1.2	68
28	Longitudinal analysis of inflammation and microbiota dynamics in a model of mild chronic dextran sulfate sodium-induced colitis in mice. World Journal of Gastroenterology, 2014, 20, 2051.	1.4	66
29	Brain functional changes in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 1769-1777.	0.9	65
30	Mesalazine 4 g Daily Given as Prolonged-Release Granules Twice Daily and Four Times Daily Is at Least as Effective as Prolonged-Release Tablets Four Times Daily in Patients with Ulcerative Colitis. Inflammatory Bowel Diseases, 2001, 7, 237-242.	0.9	62
31	Probiotic Therapy in the Prevention of Pouchitis Onset: Decreased Interleukin-1β, Interleukin-8, and Interferon-γ Gene Expression. Inflammatory Bowel Diseases, 2005, 11, 447-454.	0.9	61
32	Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine. Journal of Clinical Gastroenterology, 2005, 39, 291-297.	1.1	59
33	Functional magnetic resonance imaging study reveals differences in the habituation to psychological stress in patients with Crohn's disease versus healthy controls. Journal of Behavioral Medicine, 2013, 36, 477-487.	1.1	51
34	Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources. Food Chemistry, 2015, 176, 167-174.	4.2	51
35	Importance of Laboratory Parameters in the Evaluation of Crohn's Disease Activity. Journal of Clinical Gastroenterology, 1986, 8, 245-248.	1.1	49
36	Cutaneous Manifestations in Inflammatory Bowel Diseases: Eight Cases of Psoriasis Induced by Anti-Tumor-Necrosis-Factor Antibody Therapy. Dermatology, 2007, 215, 295-300.	0.9	49

#	Article	IF	CITATIONS
37	Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World Journal of Gastroenterology, 2006, 12, 5987.	1.4	47
38	Antioxidant, Anti-Inflammatory, and Microbial-Modulating Activities of Essential Oils: Implications in Colonic Pathophysiology. International Journal of Molecular Sciences, 2020, 21, 4152.	1.8	43
39	Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1268-1275.e2.	2.4	42
40	Probiotics for the treatment of postoperative complications following intestinal surgery. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 821-831.	1.0	41
41	Prevalence and effectiveness of psychiatric treatments for patients with IBD: A systematic literature review. Journal of Psychosomatic Research, 2017, 101, 68-95.	1.2	39
42	Refractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection. Inflammatory Bowel Diseases, 2020, 26, 321-330.	0.9	38
43	Comparison of scintigraphy with indium-111 leukocyte scan and ultrasonography in assessment of x-ray-demonstrated lesions of crohn's disease. Digestive Diseases and Sciences, 1993, 38, 433-437.	1.1	37
44	Diagnosis and treatment of pouchitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 75-87.	1.0	37
45	Standard Treatment of Ulcerative Colitis. Digestive Diseases, 2003, 21, 157-167.	0.8	37
46	Risk of permanent stoma in extensive <scp>C</scp> rohn's colitis: the impact of biological drugs. Colorectal Disease, 2013, 15, 1115-1122.	0.7	37
47	Oral beclomethasone dipropionate in chronic refractory pouchitis. Journal of Crohn's and Colitis, 2014, 8, 649-653.	0.6	37
48	Mucosal healing in pediatric Crohn's disease after anti-TNF therapy. European Journal of Gastroenterology and Hepatology, 2014, 26, 458-465.	0.8	36
49	Dietary Geraniol by Oral or Enema Administration Strongly Reduces Dysbiosis and Systemic Inflammation in Dextran Sulfate Sodium-Treated Mice. Frontiers in Pharmacology, 2016, 7, 38.	1.6	34
50	Adult Attachment and Early Parental Experiences in Patients With Crohn's Disease. Psychosomatics, 2010, 51, 208-215.	2.5	34
51	Infliximab in the treatment of Crohn's disease. Therapeutics and Clinical Risk Management, 2007, 3, 301-308.	0.9	32
52	Attachment and quality of life in patients with inflammatory bowel disease. International Journal of Colorectal Disease, 2014, 29, 1291-1296.	1.0	31
53	Prediction of relapse in patients with Crohn's disease in remission. European Journal of Gastroenterology and Hepatology, 1994, 6, 955-962.	0.8	30
54	VSL#3: An Analysis of Basic and Clinical Contributions in Probiotic Therapeutics. Gastroenterology Clinics of North America, 2005, 34, 499-513.	1.0	30

#	Article	IF	CITATIONS
55	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. Gastroenterology, 2003, 124, A377.	0.6	28
56	Parental Bonding and Inflammatory Bowel Disease. Psychosomatics, 2010, 51, 14-21.	2.5	27
57	Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo controlled trial. Gastroenterology, 2000, 118, A190.	0.6	26
58	Real-time elastography for the detection of fibrotic and inflammatory tissue in patients with stricturing Crohn's disease. Journal of Ultrasound, 2017, 20, 273-284.	0.7	26
59	Probiotics and antibiotics in inflammatory bowel disease. Current Opinion in Gastroenterology, 2001, 17, 331-335.	1.0	25
60	Sympathetic hyperactivity in patients with ulcerative colitis. Clinical Autonomic Research, 2007, 17, 217-220.	1.4	22
61	Parental Bonding and Inflammatory Bowel Disease. Psychosomatics, 2010, 51, 14-21.	2.5	22
62	The role of antibiotics and probiotics in pouchitis. Annals of Gastroenterology, 2012, 25, 100-105.	0.4	22
63	Drug delivery by polymeric micelles: an in vitro and in vivo study to deliver lipophilic substances to colonocytes and selectively target inflamed colon. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 675-685.	1.7	21
64	Management of Inflammatory Bowel Disease: Does Rifaximin Offer Any Promise?. Chemotherapy, 2005, 51, 96-102.	0.8	20
65	Obscure gastrointestinal bleeding: single centre experience of capsule endoscopy. Internal and Emergency Medicine, 2013, 8, 681-687.	1.0	20
66	Absence of change in the gray matter volume of patients with ulcerative colitis in remission: a voxel based morphometry study. BioPsychoSocial Medicine, 2015, 9, 1.	0.9	20
67	Attachment and perceived stress in patients with ulcerative colitis, a case–control study. Journal of Psychiatric and Mental Health Nursing, 2016, 23, 561-567.	1.2	20
68	Intracolonic release of nitric oxide during trinitrobenzene sulfonic acid rat colitis. Digestive Diseases and Sciences, 1997, 42, 2606-2611.	1.1	19
69	Clinical course of microscopic colitis in a single-center cohort study. Journal of Crohn's and Colitis, 2011, 5, 218-221.	0.6	19
70	CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue. International Journal of Colorectal Disease, 2004, 19, 165-170.	1.0	18
71	Dietary geraniol ameliorates intestinal dysbiosis and relieves symptoms in irritable bowel syndrome patients: a pilot study. BMC Complementary and Alternative Medicine, 2018, 18, 338.	3.7	18
72	Attachment and Mentalizing Abilities in Patients with Inflammatory Bowel Disease. Gastroenterology Research and Practice, 2019, 2019, 1-7.	0.7	18

#	Article	IF	CITATIONS
73	Eviendep [®] reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World Journal of Gastroenterology, 2013, 19, 5671.	1.4	18
74	Probiotics in gastroenterology. Current Opinion in Gastroenterology, 2002, 18, 235-239.	1.0	15
75	Respiratory burst of circulating polymorphonuclear leukocytes and plasma elastase levels in patients with inflammatory bowel disease in remission. Digestive Diseases and Sciences, 1994, 39, 550-554.	1.1	13
76	Management of pouch dysfunction or pouchitis with an ileoanal pouch. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 993-1006.	1.0	12
77	Antibiotics and probiotics in chronic pouchitis: a comparative proteomic approach. World Journal of Gastroenterology, 2010, 16, 30-41.	1.4	12
78	Role of conventional therapies in the era of biological treatment in Crohn's disease. World Journal of Gastroenterology, 2011, 17, 1797.	1.4	11
79	Relapsing ulcerative colitis after spinal cord stimulation: A case of intestinal neurogenic inflammation?. Gastroenterology, 1999, 117, 1256-1257.	0.6	9
80	Probiotic Therapy to Prevent Pouchitis Onset. Diseases of the Colon and Rectum, 2005, 48, 1493.	0.7	9
81	The role of Budesonide-MMX in active ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 215-222.	1.4	9
82	Can supplementation of phytoestrogens/insoluble fibers help the management of duodenal polyps in familial adenomatous polyposis?. Carcinogenesis, 2016, 37, 600-606.	1.3	8
83	The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opinion on Drug Safety, 2018, 17, 963-969.	1.0	8
84	Four cases of carcinoid tumour in Crohn's disease: coincidence or correlation?. International Journal of Colorectal Disease, 2013, 28, 1743-1745.	1.0	5
85	Ancient pathogen-driven adaptation triggers increased susceptibility to non-celiac wheat sensitivity in present-day European populations. Genes and Nutrition, 2016, 11, 15.	1.2	5
86	Sporadic small bowel tumors detected by capsule endoscopy in patients with occult gastrointestinal bleeding. Internal and Emergency Medicine, 2015, 10, 781-785.	1.0	4
87	SKIN TESTS FOR CÅ'LIAC DISEASE. Lancet, The, 1979, 313, 611.	6.3	3
88	Serum zinc concentrations in Crohn's disease. Digestive Diseases and Sciences, 1982, 27, 1141-1142.	1.1	1
89	Efficacy of a symbiotic preparation on functional intestinal disorders (FD) with altered bowel habit: A doublblind controlled study. Gastroenterology, 2001, 120, A750-A751.	0.6	1
90	What Is the Best Initial Treatment and Maintenance Therapy for Distal Ulcerative Colitis?. Inflammatory Bowel Diseases, 1996, 2, 306-307.	0.9	0

#	Article	IF	CITATIONS
91	Attualità e controversie nella terapia delle malattie infiammatorie croniche intestinali. Italian Journal of Medicine, 2009, 3, 179-186.	0.2	0
92	Adalimumab in a patient with steroid-dependent Crohn's disease. Digestive and Liver Disease Supplements, 2010, 4, 38-39.	0.2	0
93	News and controversy in inflammatory bowel disease treatment. Italian Journal of Medicine, 2013, , 179-186.	0.2	0
94	Clinical management of severe active ulcerative colitis in the TNF-a inhibitors era. Italian Journal of Medicine, 2013, 7, 272.	0.2	0
95	Risks and Benefits of Mucosal Healing With Combined Immunosuppression in Paediatric Crohn's Disease: A Complex Topic That Needs Careful Evaluation. Journal of Crohn's and Colitis, 2016, 11, jjw220.	0.6	Ο
96	Cell proliferation of esophageal squamous epithelium in erosive and non-erosive reflux disease. World Journal of Gastroenterology, 2011, 17, 4496.	1.4	0
97	Management and treatment of distal ulcerative colitis. Italian Journal of Medicine, 2013, 7, 265.	0.2	Ο
98	Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?. Updates in Surgery Series, 2019, , 93-104.	0.0	0